This intensive 12-week doctoral internship focuses on advancing the mechanistic understanding of Antibody-Drug Conjugates (ADCs) through sophisticated Model-Informed Drug Development (MIDD). The successful candidate will lead a high-impact project investigating the translational drivers of variability in preclinical Tumor Static Concentration (TSC) estimates across vedotin platforms. This role is pivotal in refining the modeling strategies th[ "\r\n\t\r\n\t. Curate, harmonize, and execute rigorous quality control on complex in vitro and in vivo preclinical datasets across multiple ADC programs.\r\n\t\r\n\t\r\n\t. Standardize xenograft PK/ PD model structures and refine TSC estimation methodologies to ensure cross-platform comparability.\r\n\t\r\n\t\r\n\t. Perform multivariate and model-based analyses to isolate the mechanistic drivers of TSC variability and evaluate their translational relevance.\r\n\t\r\n\t\r\n\t. Interrogate existing translational PK/ PD models, challenging assumptions to explore alternative semi-mechanistic or systems-informed modeling frameworks.\r\n\t\r\n\t\r\n\t. Translate quantitative findings into strategic recommendations for early ADC portfolio decision-making.\r\n\t\r\n\t\r\n\t. Synthesize research into a comprehensive technical summary and deliver a final presentation to a cross-functional audience of clinical pharmacology and translational scientists.\r\n\t\r\n\r\n" ][ "Required:\r\n\r\n\r\n\t\r\n\t. Current enrollment in a PhD program (4th or 5th year strongly preferred) in Pharmacometrics, Clinical Pharmacology, Biomedical Engineering, Biostatistics, or a related quantitative biological science.\r\n\t\r\n\t\r\n\t. Documented, hands-on experience in MIDD and Pharmacometrics; candidates must demonstrate the ability to execute modeling projects independently from inception to completion.\r\n\t\r\n\t\r\n\t. Advanced proficiency in R programming for data analysis and statistical modeling.\r\n\t\r\n\r\n\r\n#LI-AO 1\r\n\r\n\r\n\t\r\n\t. Strong foundational knowledge of PK/ PD concepts, including non-linear mixed-effects modeling and multivariate data interpretation.\r\n\t\r\n\t\r\n\t. Must be able to commit to a full-time, 12-week schedule (Monday-Friday) with no duration flexibility.\r\n\t\r\n\r\n\r\n. Preferred:\r\n\r\n\r\n\t\r\n\t. Direct experience with Tumor Growth Inhibition (TGI) modeling and xenograft efficacy datasets.\r\n\t\r\n\t\r\n\t. Familiarity with the pharmacology of ADCs, including payload dynamics and target-mediated drug disposition (TMDD).\r\n\t\r\n\t\r\n\t. Experience utilizing industry-standard platforms such as NONMEM, Monolix, or R-based modeling frameworks (e.g., mrgsolve, nlmixr).\r\n\t\r\n\t\r\n\t. A record of scientific contribution via peer-reviewed publications, posters, or conference presentations in the field of quantitative pharmacology.\r\n\t\r\n\r\n" ]

search terms: Intern+Clinical